Does prophylactic octreotide benefit patients undergoing elective pancreatic resection?
Yeo
C J
CJ
D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017558:Elective Surgical Procedures; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use*; D006728:Hormones / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D015282:Octreotide / Q000191:economics / Q000627:therapeutic use*; D010180:Pancreatectomy / Q000009:adverse effects / Q000145:classification; D010185:Pancreatic Fistula / Q000517:prevention & control; D016577:Pancreaticoduodenectomy / Q000009:adverse effects; D011292:Premedication; D015996:Survival Rate
D005765:Gastrointestinal Agents; D006728:Hormones; D015282:Octreotide